214 related articles for article (PubMed ID: 30138430)
1. Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells.
Rauca VF; Licarete E; Luput L; Sesarman A; Patras L; Bulzu P; Rakosy-Tican E; Banciu M
PLoS One; 2018; 13(8):e0202827. PubMed ID: 30138430
[TBL] [Abstract][Full Text] [Related]
2. Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression.
Rauca VF; Patras L; Luput L; Licarete E; Toma VA; Porfire A; Mot AC; Rakosy-Tican E; Sesarman A; Banciu M
Sci Rep; 2021 Nov; 11(1):22102. PubMed ID: 34764332
[TBL] [Abstract][Full Text] [Related]
3. The prednisolone phosphate‑induced suppression of the angiogenic function of tumor‑associated macrophages enhances the antitumor effects of doxorubicin on B16.F10 murine melanoma cells in vitro.
Licarete E; Rauca VF; Luput L; Patras L; Sesarman A; Banciu M
Oncol Rep; 2019 Dec; 42(6):2694-2705. PubMed ID: 31578578
[TBL] [Abstract][Full Text] [Related]
4. Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress.
Alupei MC; Licarete E; Patras L; Banciu M
Cancer Lett; 2015 Jan; 356(2 Pt B):946-52. PubMed ID: 25444912
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of lipophilic statins depends on their combined actions on HIF-1α expression and redox status in B16.F10 melanoma cells.
Alupei MC; Licarete E; Cristian FB; Banciu M
Anticancer Drugs; 2014 Apr; 25(4):393-405. PubMed ID: 24441744
[TBL] [Abstract][Full Text] [Related]
6. HIF-1α acts as a molecular target for simvastatin cytotoxicity in B16.F10 melanoma cells cultured under chemically induced hypoxia.
Licarete E; Sesarman A; Rauca VF; Luput L; Patras L; Banciu M
Oncol Lett; 2017 May; 13(5):3942-3950. PubMed ID: 28521491
[TBL] [Abstract][Full Text] [Related]
7. Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors.
Smolarczyk R; Cichoń T; Pilny E; Jarosz-Biej M; Poczkaj A; Kułach N; Szala S
Sci Rep; 2018 May; 8(1):7355. PubMed ID: 29743548
[TBL] [Abstract][Full Text] [Related]
8. Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment.
Licarete E; Rauca VF; Luput L; Drotar D; Stejerean I; Patras L; Dume B; Toma VA; Porfire A; Gherman C; Sesarman A; Banciu M
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340166
[TBL] [Abstract][Full Text] [Related]
9. Active Tumor-Targeting Nano-formulations Containing Simvastatin and Doxorubicin Inhibit Melanoma Growth and Angiogenesis.
Negrea G; Rauca VF; Meszaros MS; Patras L; Luput L; Licarete E; Toma VA; Porfire A; Muntean D; Sesarman A; Banciu M
Front Pharmacol; 2022; 13():870347. PubMed ID: 35450036
[TBL] [Abstract][Full Text] [Related]
10. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma.
Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J
Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979
[TBL] [Abstract][Full Text] [Related]
12. M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma.
Jarosz-Biej M; Kamińska N; Matuszczak S; Cichoń T; Pamuła-Piłat J; Czapla J; Smolarczyk R; Skwarzyńska D; Kulik K; Szala S
PLoS One; 2018; 13(1):e0191012. PubMed ID: 29320562
[TBL] [Abstract][Full Text] [Related]
13. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
14. Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors.
Kes MMG; Van den Bossche J; Griffioen AW; Huijbers EJM
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188427. PubMed ID: 32961257
[TBL] [Abstract][Full Text] [Related]
15. The Inhibitory Effect of Propylene Glycol Alginate Sodium Sulfate on Fibroblast Growth Factor 2-Mediated Angiogenesis and Invasion in Murine Melanoma B16-F10 Cells In Vitro.
Ma H; Qiu P; Xu H; Xu X; Xin M; Chu Y; Guan H; Li C; Yang J
Mar Drugs; 2019 Apr; 17(5):. PubMed ID: 31035725
[TBL] [Abstract][Full Text] [Related]
16. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Lu L; Payvandi F; Wu L; Zhang LH; Hariri RJ; Man HW; Chen RS; Muller GW; Hughes CC; Stirling DI; Schafer PH; Bartlett JB
Microvasc Res; 2009 Mar; 77(2):78-86. PubMed ID: 18805433
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner.
Chen P; Huang Y; Bong R; Ding Y; Song N; Wang X; Song X; Luo Y
Clin Cancer Res; 2011 Dec; 17(23):7230-9. PubMed ID: 21994414
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cell proliferation, migration and invasion of B16-F10 melanoma cells by α-mangostin.
Beninati S; Oliverio S; Cordella M; Rossi S; Senatore C; Liguori I; Lentini A; Piredda L; Tabolacci C
Biochem Biophys Res Commun; 2014 Aug; 450(4):1512-7. PubMed ID: 25019992
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of alpha(4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with gambogic acid.
Zhao J; Qi Q; Yang Y; Gu HY; Lu N; Liu W; Wang W; Qiang L; Zhang LB; You QD; Guo QL
Eur J Pharmacol; 2008 Jul; 589(1-3):127-31. PubMed ID: 18539272
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhao L; Marshall ES; Kelland LR; Baguley BC
Invest New Drugs; 2007 Jun; 25(3):271-6. PubMed ID: 17203401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
